Home » Topics » Regulatory » EMA

EMA
RSS

EMA committee backs approval of Janssen's Symtuza

July 24, 2017

EMA's CHMP grants positive opinion for dupixent for the treatment of atopic dermatitis

July 24, 2017

EMA committee recommends approval of label update for Lixiana

July 17, 2017

EMA validates pacritinib MAA for patients with myelofibrosis who have thrombocytopenia

July 14, 2017

Gilead Sciences' MAA for bictegravir/emtricitabine/tenofovir alafenamide FDC validated by EMA

July 14, 2017

ProQR Therapeutics receives orphan drug designations in E.U. and U.S. for QRX-411

July 7, 2017

RDD Pharma's RDD-0315 given orphan drug status in E.U.

July 7, 2017

Polatuzumab vedotin is eligible for access to EMA's PRIME program

June 30, 2017

Global Blood Therapeutics' GBT-440 obtains EMA PRIME designation

June 29, 2017

Stivarga for HCC approved in Japan, recommended for approval in E.U.

June 27, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 23, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...